MA46887A - Sulfonation sélective de dérivés de benzodiazépine - Google Patents

Sulfonation sélective de dérivés de benzodiazépine

Info

Publication number
MA46887A
MA46887A MA046887A MA46887A MA46887A MA 46887 A MA46887 A MA 46887A MA 046887 A MA046887 A MA 046887A MA 46887 A MA46887 A MA 46887A MA 46887 A MA46887 A MA 46887A
Authority
MA
Morocco
Prior art keywords
sulphonation
selective
benzodiazepine derivatives
benzodiazepine
derivatives
Prior art date
Application number
MA046887A
Other languages
English (en)
Inventor
Scott A Hilderbrand
Benjamin M Hutchins
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MA46887A publication Critical patent/MA46887A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
MA046887A 2016-11-23 2017-11-22 Sulfonation sélective de dérivés de benzodiazépine MA46887A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662425761P 2016-11-23 2016-11-23

Publications (1)

Publication Number Publication Date
MA46887A true MA46887A (fr) 2019-10-02

Family

ID=60655118

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046887A MA46887A (fr) 2016-11-23 2017-11-22 Sulfonation sélective de dérivés de benzodiazépine

Country Status (11)

Country Link
US (5) US10287256B2 (fr)
EP (1) EP3544983A2 (fr)
JP (2) JP7203729B2 (fr)
KR (2) KR20230133935A (fr)
CN (2) CN116813690A (fr)
AU (2) AU2017363237B2 (fr)
CA (1) CA3044391A1 (fr)
IL (2) IL266743B (fr)
MA (1) MA46887A (fr)
TW (2) TW202235109A (fr)
WO (1) WO2018098258A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61452B9 (sr) 2015-06-29 2021-12-31 Immunogen Inc Anti-cd123 antitela i njihovi konjugati i derivati
WO2018098258A2 (fr) * 2016-11-23 2018-05-31 Immunogen, Inc. Sulfonation sélective de dérivés de benzodiazépine
CN113329768A (zh) 2018-10-30 2021-08-31 伊缪诺金公司 使用抗cd123免疫缀合物的治疗方法
CA3133802A1 (fr) * 2019-03-21 2020-09-24 Immunogen, Inc. Procedes de preparation de conjugues agent de liaison cellulaire-medicament
AU2020265225A1 (en) 2019-04-29 2021-10-28 Immunogen, Inc. Therapeutic combinations comprising anti-CD123 immunoconjugates
AU2020347257A1 (en) 2019-09-13 2022-04-28 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
WO2004013093A2 (fr) 2002-08-02 2004-02-12 Immunogen, Inc. Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2558399C (fr) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Anticorps partiellement charges et procedes de conjugaison desdits anticorps
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
CA2587589A1 (fr) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
SI1879901T1 (sl) 2005-04-21 2010-04-30 Spirogen Ltd Pirolobenzodiazepini
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2652945C (fr) 2006-05-30 2015-06-02 Genentech, Inc. Anticorps et immuno-conjugues, et leurs utilisations
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
DK2281006T3 (da) 2008-04-30 2017-11-06 Immunogen Inc Tværbindingsmidler og anvendelser deraf
WO2009134976A1 (fr) 2008-04-30 2009-11-05 Immunogen, Inc Conjugués puissants et coupleurs hydrophiles
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
KR101835033B1 (ko) 2009-02-05 2018-03-08 이뮤노젠 아이엔씨 신규한 벤조디아제핀 유도체
CN102802661B (zh) 2009-06-22 2016-01-13 米迪缪尼有限公司 用于位点特异性偶联的工程改造的Fc区
WO2011092838A1 (fr) 2010-01-29 2011-08-04 株式会社フォーサイド・ドット・コム Système de partage de contenu et procédé de partage de contenu
NZ724971A (en) 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
ES2748347T3 (es) 2010-03-12 2020-03-16 Debiopharm Int Sa Moléculas de unión a CD37 e inmunoconjugados de las mismas
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
NZ701825A (en) 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
CA2824864C (fr) 2011-02-15 2019-04-09 Immunogen, Inc. Derives cytotoxiques de benzodiazepine
WO2013177481A1 (fr) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazépines et leurs conjugués
WO2014134457A2 (fr) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
EP2961435B1 (fr) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
EP2961434A2 (fr) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
NZ717003A (en) * 2013-09-02 2019-05-31 Hangzhou Dac Biotech Co Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
BR112016029860A2 (pt) 2014-06-20 2017-10-24 Abgenomics Int Inc conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
KR20170027774A (ko) 2014-06-20 2017-03-10 바이오얼라이언스 씨.브이. 항-cd22 항체-약물 컨쥬게이트 및 그것의 사용 방법
SG11201701328XA (en) 2014-09-02 2017-03-30 Immunogen Inc Methods for formulating antibody drug conjugate compositions
TW201613930A (en) * 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
TWI757759B (zh) 2014-09-03 2022-03-11 美商免疫原公司 細胞毒性苯并二氮呯衍生物
MA41645A (fr) 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
RS61452B9 (sr) 2015-06-29 2021-12-31 Immunogen Inc Anti-cd123 antitela i njihovi konjugati i derivati
CA2988806A1 (fr) * 2015-06-29 2017-01-05 Immunogen, Inc. Conjugues d'anticorps a cysteine modifiee
US20190038762A1 (en) 2016-02-05 2019-02-07 Millennium Pharmaceuticals, Inc. Gcc-targeted antibody-drug conjugates
WO2018098258A2 (fr) * 2016-11-23 2018-05-31 Immunogen, Inc. Sulfonation sélective de dérivés de benzodiazépine

Also Published As

Publication number Publication date
RU2019118808A (ru) 2020-12-24
US20200157056A1 (en) 2020-05-21
KR102576550B1 (ko) 2023-09-07
AU2022204163A1 (en) 2022-07-21
CN110392685A (zh) 2019-10-29
IL291597A (en) 2022-05-01
US20210101871A1 (en) 2021-04-08
US10287256B2 (en) 2019-05-14
JP7203729B2 (ja) 2023-01-13
IL266743A (en) 2019-07-31
KR20230133935A (ko) 2023-09-19
US20190315699A1 (en) 2019-10-17
CA3044391A1 (fr) 2018-05-31
CN110392685B (zh) 2023-07-04
WO2018098258A3 (fr) 2018-10-04
WO2018098258A2 (fr) 2018-05-31
TWI755450B (zh) 2022-02-21
US20180208562A1 (en) 2018-07-26
CN116813690A (zh) 2023-09-29
KR20190104995A (ko) 2019-09-11
US20230391733A1 (en) 2023-12-07
EP3544983A2 (fr) 2019-10-02
TW201822819A (zh) 2018-07-01
US11572349B2 (en) 2023-02-07
AU2017363237B2 (en) 2022-03-17
IL266743B (en) 2022-04-01
AU2017363237A1 (en) 2019-06-27
RU2019118808A3 (fr) 2021-03-19
JP2020512276A (ja) 2020-04-23
US10822313B2 (en) 2020-11-03
TW202235109A (zh) 2022-09-16
JP2023036842A (ja) 2023-03-14
US10494348B2 (en) 2019-12-03

Similar Documents

Publication Publication Date Title
MA46887A (fr) Sulfonation sélective de dérivés de benzodiazépine
MA41898A (fr) Dérivés de quinazolinone bicyclique
CL2017000739S1 (es) Foco delantero para automóvil
DK3458443T3 (da) Aromatiske sulfonamidderivater
MA54254A (fr) Dérivés de benzodiazépine cytotoxique
DK3464309T3 (da) Phosphoramidatnukleosidderivater som anticancermidler
DK3458100T3 (da) Selektiv reduktion af cystein-manipulerede antistoffer
DK3558995T3 (da) Polymorfer
MA42049A (fr) Sulfones tricycliques utiles commes modulateurs ror-gamma
DK3558961T3 (da) Polymorfer
DE112017003628A5 (de) Fortbewegungshilfe
CL2016002143S1 (es) Inodoro
ES1228911Y (es) Anillo de inodoro para mascotas
DK3430004T3 (da) Faststofformer af nilotinibsalte
MA54257A (fr) Plaque de platre
MA42679A (fr) Dérivés de pyrrolidin-2-one annelés antibactériens
ITUA20162224A1 (it) Procedimento per filettare corpi tubolari
ES1150811Y (es) Torniquete sanitario
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA44018A (fr) Dérivés de tétrahydroisoquinoline
MA41641A (fr) Dérivés de tétrahydropyranylbenzamide
ES1192458Y (es) Cespol para instalaciones de griferia
DK3506765T3 (da) Fremgangsmåde til skylning af kødkroppe
ES2703386T8 (es) Procedimiento para la purificación de hidrocarburos
BR112017026807A2 (pt) agentes solubilizantes para compostos ativos funcionais